Want to join the conversation?
CEO Leonard Schleifer said that $REGN's pipeline of opportunities continues to grow with a total of 15 product candidates currently in clinical development, including the 7 products that company develops independently. He added that several more products are expected in the near-term, creating potential opportunities for the company.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.